Trial · NCT01708278
Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)
NCT01708278, Phase 1, Completed, University of Michigan; results first posted 2016-12-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD). Trials, record NCT01708278. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01708278
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)
- NCT number
- NCT01708278
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 9 participants, actual
- Lead sponsor
- University of Michigan
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Quercetin, Placebo - sugar chew
- First posted
- 2012-10-16
- Last updated
- 2016-12-26
- Results first posted
- 2016-12-26
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Participants Who Experienced Safety Concerns, Where Safety Concerns of Quercetin Supplementation is Indicated by Significant Change From Baseline Measures of Tests Indicated Below in Outcome Measure Description | One week in Phase I safety study | Note: If values for any of the measures indicated here were found, the participant would be indicated as a participant with a safety concern, and values for that particular measure would be posted specifically, but since none of the participants experienced these outlying values, results of all tests are expressed here as a composite function. PULMONARY FUNCTION TEST: FEV1% of predicted: decline by \>20% from baseline COMPLETE BLOOD COUNTS: WBC (cells)/mm3 : \<2000, Platelets (cells)/mm3: \<25,000, Hemoglobin (g/dL): \<7.0 COMPREHENSIVE METABOLIC PROFILE (study drug related):Sodium (mmol/L): \<125 or \>148, Potassium (mmol/L): \< 3.0 or \> 6.0, Calcium (mmol/L): \<7.4 or \> 11.5, LIVER FUNCTION TESTS INCREASE BY FACTOR: Enzymes ALT, AST, and Alkaline phosphate, Total bilirubin: for any of these a value \>3X upper limit of normal |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Participants Who Experienced Safety Concerns, Where Safety Concerns of Quercetin Supplementation is Indicated by Significant Change From Baseline Measures of Tests Indicated Below in Outcome Measure Description | One week in Phase I safety study | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Participants Who Experienced Safety Concerns, Where Safety Concerns of Quercetin Supplementation is Indicated by Significant Change From Baseline Measures of Tests Indicated Below in Outcome Measure Description | Sugar Chew- Cohort 1 | 0 | Participants | ||
Participants Who Experienced Safety Concerns, Where Safety Concerns of Quercetin Supplementation is Indicated by Significant Change From Baseline Measures of Tests Indicated Below in Outcome Measure Description | Quercetin 1-Cohort 1 | 0 | Participants | ||
Participants Who Experienced Safety Concerns, Where Safety Concerns of Quercetin Supplementation is Indicated by Significant Change From Baseline Measures of Tests Indicated Below in Outcome Measure Description | Quercetin 2-Cohort 2 | 0 | Participants | ||
Participants Who Experienced Safety Concerns, Where Safety Concerns of Quercetin Supplementation is Indicated by Significant Change From Baseline Measures of Tests Indicated Below in Outcome Measure Description | Quercetin 3-Cohort 3 | 0 | Participants | ||
Participants Who Experienced Safety Concerns, Where Safety Concerns of Quercetin Supplementation is Indicated by Significant Change From Baseline Measures of Tests Indicated Below in Outcome Measure Description | Sugar Chew-Cohort 2 | 0 | Participants | ||
Participants Who Experienced Safety Concerns, Where Safety Concerns of Quercetin Supplementation is Indicated by Significant Change From Baseline Measures of Tests Indicated Below in Outcome Measure Description | Sugar Chew-Cohort 3 | 0 | Participants |
Source ClinicalTrials.gov
Participant flow18
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Sugar Chew- Cohort 1 | 1 | |
| Overall Study | STARTED | Quercetin 1-Cohort 1 | 2 | |
| Overall Study | STARTED | Quercetin 2-Cohort 2 | 2 | |
| Overall Study | STARTED | Quercetin 3-Cohort 3 | 2 | |
| Overall Study | STARTED | Sugar Chew-Cohort 2 | 1 | |
| Overall Study | STARTED | Sugar Chew-Cohort 3 | 1 | |
| Overall Study | COMPLETED | Sugar Chew- Cohort 1 | 1 | |
| Overall Study | COMPLETED | Quercetin 1-Cohort 1 | 2 | |
| Overall Study | COMPLETED | Quercetin 2-Cohort 2 | 2 | |
| Overall Study | COMPLETED | Quercetin 3-Cohort 3 | 2 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 participant flowAdverse events48
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Heart burn, GERD | Gastrointestinal disorders | Sugar Chew-Cohort 1 | 1 | 1 | |
| other | Heart burn, GERD | Gastrointestinal disorders | Quercetin 1-Cohort 1 | 1 | 2 | |
| other | Heart burn, GERD | Gastrointestinal disorders | Quercetin 2-Cohort 2 | 1 | 2 | |
| other | Heart burn, GERD | Gastrointestinal disorders | Quercetin 3-Cohort 3 | 0 | 2 | |
| other | Heart burn, GERD | Gastrointestinal disorders | Sugar Chew-Cohort 2 | 0 | 0 | |
| other | Heart burn, GERD | Gastrointestinal disorders | Sugar Chew-Cohort 3 | 0 | 1 | |
| other | Nausea | Gastrointestinal disorders | Sugar Chew-Cohort 1 | 0 | 1 | |
| other | Nausea | Gastrointestinal disorders | Quercetin 1-Cohort 1 | 0 | 2 | |
| other | Nausea | Gastrointestinal disorders | Quercetin 2-Cohort 2 | 0 | 2 | |
| other | Nausea | Gastrointestinal disorders | Quercetin 3-Cohort 3 | 0 | 2 |
1 to 10 of 48Source ClinicalTrials.gov
See all 48 adverse eventsAdverse event totals18
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Sugar Chew-Cohort 1 | ||
| Total, all-cause mortality | Quercetin 1-Cohort 1 | ||
| Total, all-cause mortality | Quercetin 2-Cohort 2 | ||
| Total, all-cause mortality | Quercetin 3-Cohort 3 | ||
| Total, all-cause mortality | Sugar Chew-Cohort 2 | ||
| Total, all-cause mortality | Sugar Chew-Cohort 3 | ||
| Total, other adverse events | Sugar Chew-Cohort 1 | 1 | 1 |
| Total, other adverse events | Quercetin 1-Cohort 1 | 2 | 2 |
| Total, other adverse events | Quercetin 2-Cohort 2 | 2 | 2 |
| Total, other adverse events | Quercetin 3-Cohort 3 | 1 | 2 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 adverse event totalsPapers11
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R21AT007357 | Beneficial effects of quercetin in COPD - a preliminary clinical trial | SAJJAN, UMADEVI SIVANAPPA; MARTINEZ, FERNANDO J | UNIVERSITY OF MICHIGAN AT ANN ARBOR | NATIONAL CENTER FOR COMPLEMENTARY & INTEGRATIVE HEALTH | 2012 to 2014 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01708278
GET https://conductscience.org/api/trials/v1/NCT01708278/events?page=2